Last reviewed · How we verify

Tranexamic Acid (IV)

Samsung Medical Center · FDA-approved active Small molecule ✓ Verified May 2026

Tranexamic Acid (IV) is a Antifibrinolytic agent Small molecule drug developed by Samsung Medical Center. It is currently FDA-approved for Reduction of blood loss in surgical procedures, Treatment of heavy menstrual bleeding, Management of bleeding in hemophilia and other bleeding disorders. Also known as: TXA, Cyklokapron, Lysteda, Transamin..

Tranexamic acid inhibits the activation of plasminogen to plasmin, thereby reducing fibrinolysis and promoting blood clot stability.

Tranexamic acid inhibits the activation of plasminogen to plasmin, thereby reducing fibrinolysis and promoting blood clot stability. Used for Reduction of blood loss in surgical procedures, Treatment of heavy menstrual bleeding, Management of bleeding in hemophilia and other bleeding disorders.

At a glance

Generic nameTranexamic Acid (IV)
Also known asTXA, Cyklokapron, Lysteda, Transamin., Cyclokapron
SponsorSamsung Medical Center
Drug classAntifibrinolytic agent
TargetPlasminogen / Plasmin
ModalitySmall molecule
Therapeutic areaHematology / Hemostasis
PhaseFDA-approved

Mechanism of action

Tranexamic acid is an antifibrinolytic agent that competitively inhibits the binding of plasminogen and plasmin to fibrin. By blocking fibrinolysis, it stabilizes formed blood clots and reduces excessive bleeding. It is commonly used to reduce blood loss in surgical procedures and manage bleeding in various clinical conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tranexamic Acid (IV)

What is Tranexamic Acid (IV)?

Tranexamic Acid (IV) is a Antifibrinolytic agent drug developed by Samsung Medical Center, indicated for Reduction of blood loss in surgical procedures, Treatment of heavy menstrual bleeding, Management of bleeding in hemophilia and other bleeding disorders.

How does Tranexamic Acid (IV) work?

Tranexamic acid inhibits the activation of plasminogen to plasmin, thereby reducing fibrinolysis and promoting blood clot stability.

What is Tranexamic Acid (IV) used for?

Tranexamic Acid (IV) is indicated for Reduction of blood loss in surgical procedures, Treatment of heavy menstrual bleeding, Management of bleeding in hemophilia and other bleeding disorders, Trauma-associated hemorrhage.

Who makes Tranexamic Acid (IV)?

Tranexamic Acid (IV) is developed and marketed by Samsung Medical Center (see full Samsung Medical Center pipeline at /company/samsung-medical-center).

Is Tranexamic Acid (IV) also known as anything else?

Tranexamic Acid (IV) is also known as TXA, Cyklokapron, Lysteda, Transamin., Cyclokapron.

What drug class is Tranexamic Acid (IV) in?

Tranexamic Acid (IV) belongs to the Antifibrinolytic agent class. See all Antifibrinolytic agent drugs at /class/antifibrinolytic-agent.

What development phase is Tranexamic Acid (IV) in?

Tranexamic Acid (IV) is FDA-approved (marketed).

What are the side effects of Tranexamic Acid (IV)?

Common side effects of Tranexamic Acid (IV) include Thromboembolic events (deep vein thrombosis, pulmonary embolism), Nausea and vomiting, Diarrhea, Headache, Visual disturbances.

What does Tranexamic Acid (IV) target?

Tranexamic Acid (IV) targets Plasminogen / Plasmin and is a Antifibrinolytic agent.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing